$5.45 Billion is the total value of Redmile Group, LLC's 81 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GILD | New | GILEAD SCIENCES INC | $181,353,000 | – | 2,869,962 | +100.0% | 3.33% | – |
| OSH | New | OAK STR HEALTH INC | $141,745,000 | – | 2,652,411 | +100.0% | 2.60% | – |
| ANNX | New | ANNEXON INC | $104,055,000 | – | 3,442,122 | +100.0% | 1.91% | – |
| NRIX | New | NURIX THERAPEUTICS INC | $90,542,000 | – | 2,593,570 | +100.0% | 1.66% | – |
| KYMR | New | KYMERA THERAPEUTICS INC | $88,292,000 | – | 2,732,660 | +100.0% | 1.62% | – |
| ALVR | New | ALLOVIR INC | $64,168,000 | – | 2,333,390 | +100.0% | 1.18% | – |
| RCEL | New | AVITA THERAPEUTICS INC | $44,774,000 | – | 1,779,586 | +100.0% | 0.82% | – |
| IMTX | New | IMMATICS N.V | $22,599,000 | – | 2,130,000 | +100.0% | 0.42% | – |
| CTSO | New | CYTOSORBENTS CORP | $16,757,000 | – | 2,101,131 | +100.0% | 0.31% | – |
| ALXO | New | ALX ONCOLOGY HLDGS INC | $15,375,000 | – | 407,400 | +100.0% | 0.28% | – |
| PAND | New | PANDION THERAPEUTICS INC | $12,831,000 | – | 1,119,600 | +100.0% | 0.24% | – |
| FSDC | New | FS DEV CORP | $11,200,000 | – | 1,000,000 | +100.0% | 0.21% | – |
| GDRX | New | GOODRX HLDGS INC | $11,120,000 | – | 200,000 | +100.0% | 0.20% | – |
| OM | New | OUTSET MED INC | $3,500,000 | – | 70,000 | +100.0% | 0.06% | – |
| RIGL | New | RIGEL PHARMACEUTICALS INC | $1,787,000 | – | 744,582 | +100.0% | 0.03% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 43 | Q3 2023 | 10.1% |
| ATARA BIOTHERAPEUTICS INC | 36 | Q3 2023 | 6.4% |
| FATE THERAPEUTICS INC | 34 | Q3 2023 | 17.2% |
| INVITAE CORP | 32 | Q3 2023 | 2.7% |
| REGENXBIO INC | 28 | Q3 2023 | 3.8% |
| CLOVIS ONCOLOGY INC | 27 | Q1 2020 | 6.7% |
| IMMUNOGEN INC | 27 | Q3 2023 | 13.2% |
| CASTLIGHT HEALTH INC SAN FRAN COM STK | 27 | Q1 2021 | 2.5% |
| ARRAY BIOPHARMA INC | 26 | Q2 2019 | 12.6% |
| DECIPHERA PHARMACEUTICALS IN | 25 | Q3 2023 | 7.0% |
View Redmile Group, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | July 27, 2023 | 2,912,228 | 6.6% |
| IGM Biosciences, Inc. | June 28, 2023 | 3,291,092 | 9.9% |
| MedAvail Holdings, Inc. | June 21, 2023 | 124,507,268 | 73.1% |
| Achilles Therapeutics plc | February 14, 2023 | 1,608,089 | 3.9% |
| Kymera Therapeutics, Inc. | February 14, 2023 | 2,673,837 | 4.9% |
| Old Ayala, IncSold out | February 08, 2023 | 0 | 0.0% |
| Zymeworks Inc. | August 08, 2022 | 5,758,241 | 9.9% |
| Science 37 Holdings, Inc. | June 15, 2022 | 19,808,234 | 17.1% |
| Allakos Inc. | February 14, 2022 | 2,077,875 | 3.8% |
| Aprea Therapeutics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
View Redmile Group, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-03-25 |
| SC 13D/A | 2024-03-25 |
| 4 | 2024-03-19 |
| 4 | 2024-03-14 |
| 4 | 2024-03-13 |
| SC 13D/A | 2024-03-13 |
| 4 | 2024-03-05 |
| SC 13D/A | 2024-03-05 |
View Redmile Group, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.